Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.

Since its launch, Rezdiffra has made steady commercial progress. In the third quarter, Madrigal's single approved product ...

Previously, Galmed announced the grant of new use patent for a combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH. The new patent extends Aramchol's patent ...

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

Investing.com -- Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock gained 3.7% on Thursday after the company announced it received a new patent in South Korea for its lead compound Aramchol in ...

Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...

ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early ...

Galmed Pharmaceuticals ( ($GLMD) ) has shared an update. On December 4, 2025, Galmed Pharmaceuticals announced the grant of a new use patent in ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.